Print page |
E-mail page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
To access the webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm. Alternatively, callers may participate in the conference call by dialing (877) 303-6133 (U.S. participants) or (970) 315-0493 (international participants).
A replay of the conference call will be available approximately two
hours after the completion of the call through
About
Osiris and Genzyme formed a strategic alliance for the development and
commercialization of Prochymal and Chondrogen. Under the terms of the
agreement, Osiris retains commercialization rights to Prochymal and
Chondrogen in
Osiris and Prochymal are registered trademarks of
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking
statements include statements about our expectations, beliefs, plans,
objectives, intentions, assumptions and other statements that are not
historical facts. Words or phrases such as "anticipate," "believe,"
"continue," "ongoing," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project" or similar words or phrases, or the
negatives of those words or phrases, may identify forward-looking
statements, but the absence of these words does not necessarily mean
that a statement is not forward-looking. Examples of forward-looking
statements include, but are not limited to, statements regarding the
following: our product development efforts; our clinical trials and
anticipated regulatory requirements and the ability to successfully
navigate these requirements; the success of our product candidates in
development; status of the regulatory process for our biologic drug
candidates; implementation of our corporate strategy; our financial
performance; our product research and development activities and
projected expenditures, including our anticipated timeline and clinical
strategy for Prochymal, Chondrogen and our other mesenchymal stem cell
(MSC) and biologic drug candidates; our cash needs; patents and
proprietary rights; the safety and ability of our potential products to
treat disease and the results of our scientific research; our plans for
sales and marketing; our plans regarding our facilities; types of
regulatory frameworks we expect will be applicable to our potential
products; and results of our scientific research. Forward-looking
statements are subject to known and unknown risks and uncertainties and
are based on potentially inaccurate assumptions that could cause actual
results to differ materially from those expected or implied by the
forward-looking statements. Risks and uncertainties related to our
Collaboration Agreement with Genzyme for the development and
commercialization of Prochymal and Chondrogen include, among others:
typical business transactional risks; risks related to product
development and clinical trial design, performance and completion;
uncertainty of the success of Prochymal and Chondrogen in clinical
trials and their ability to treat disease; Genzyme's early termination
and opt-out rights; the ability of Osiris and Genzyme to successfully
navigate regulatory requirements and to manufacture and commercialize
products; and the uncertainty as to our ability to successfully perform
under the collaborative arrangement and earn milestone and royalty
payments thereunder. Our actual results could differ materially from
those anticipated in forward-looking statements for many reasons,
including the factors described in the section entitled "Risk Factors"
in our Annual Report on Form 10-K and other Periodic Reports filed on
Form 10-Q, with the
OsirisPR@Osiris.com
Source:
News Provided by Acquire Media